Amprion Secures $15 Million Funding for Neurologic Diagnostics
Amprion, a pioneering force in neurodegenerative disorder diagnostics, has announced the successful closing of an initial $6 million as part of a broader $15 million Series B financing effort. This funding round, which garnered significant support from Formation Venture Engineering (FVE), Eli Lilly and Company, as well as Amprion’s previous investors, marks a crucial step towards expanding the company's commercial capabilities and enhancing research and development initiatives.
Revolutionizing Neurodegenerative Diagnostics
The financing will facilitate Amprion's mission to transform how brain diseases are diagnosed. The company has developed seed amplification testing technology, which is critical for detecting small quantities of misfolded proteins in biological samples, particularly cerebrospinal fluid (CSF). This advancement is particularly impactful in diagnosing disorders such as Parkinson's disease, Lewy body dementia, and Alzheimer’s disease with neocortical Lewy body copathology.
Innovative Testing Methods
Amprion's SAAmplify-?SYN biomarker test, previously known as SYNTap, stands out as the only validated seed amplification assay aimed specifically at diagnosing synucleinopathies. This unique test not only aids in clinical diagnoses but also underscores Amprion's commitment to partnering with prominent pharmaceutical firms to develop effective therapies for neurodegenerative conditions.
Endorsements from Key Industry Leaders
Rahul Bhansali, Managing Partner at FVE, expressed their pride in supporting Amprion, emphasizing the transformative potential of biology-based diagnoses over traditional symptomology. This support reflects the confidence investors have in Amprion’s vision and technology.
In recent studies published in prestigious medical journals, such as The Lancet Neurology and Alzheimer’s and Dementia, researchers have confirmed the high sensitivity and specificity of Amprion’s testing technology. Notably, these findings have been validated through post-mortem studies, enhancing the credibility of their innovative approach.
Future Alliance and Expectations
Russell Lebovitz, MD, PhD, the CEO and co-founder of Amprion, voiced gratitude for the backing received from FVE and Eli Lilly. The company is in a favorable position, fostering strong relationships with leading neurology centers and pharmaceutical firms, indicating a robust demand for their biomarker testing technology.
Amprion is also proactive in expanding its clinical reach in the United States with recent applications submitted to the New York Department of Health. A strategic reconfiguration of its Board is in progress, focusing on incorporating three new members with specialized industry expertise to navigate regulatory landscapes and optimize growth strategies.
About SAAmplify-?SYN
The SAAmplify-?SYN Biomarker Test, recognized as a laboratory-developed test (LDT), is not only first-of-its-kind but is the only seed amplification assay available for assessing synucleinopathies. In 2019, the FDA acknowledged the test with a Breakthrough Device Designation for its invaluable role in diagnosing Parkinson's disease. Commercially launched in 2021, the test represents a significant advancement in neurodegenerative disorder diagnostics.
About Amprion
Amprion is committed to advancing the landscape of neurodegenerative disorder diagnosis through its groundbreaking seed amplification testing. The company has developed a strong intellectual property base around SAA methodology, which extends across research, drug development, and commercial applications. Its SAAmplify-?SYN biomarker test is crucial for diagnosing associated conditions. Through collaborations with biopharma partners, Amprion actively contributes to evaluating new drug candidates and improving patient outcomes.
Frequently Asked Questions
What is the purpose of Amprion's $15 million financing?
The financing aims to expand Amprion's commercial reach and boost research and development efforts for neurodegenerative disease diagnostics.
What technology does Amprion specialize in?
Amprion focuses on seed amplification testing, allowing for the detection of misfolded proteins related to various neurodegenerative disorders.
Who led the Series B financing round?
The financing round was led by Formation Venture Engineering, with participation from Eli Lilly and Amprion’s Series A investors.
What is the significance of the SAAmplify-?SYN test?
The SAAmplify-?SYN test is the only validated seed amplification assay that assists in diagnosing synucleinopathies like Parkinson’s and Alzheimer’s diseases.
How is Amprion planning to grow its clinical reach?
Amprion has submitted applications to health authorities to expand its clinical footprint and is restructuring its Board to enhance regulatory navigation.
